NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis $1.40 +0.01 (+0.72%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.34▼$1.4350-Day Range$1.10▼$1.5052-Week Range$1.05▼$11.26Volume271,578 shsAverage Volume1.16 million shsMarket Capitalization$76.91 millionP/E RatioN/ADividend YieldN/APrice Target$12.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Marinus Pharmaceuticals alerts: Email Address Marinus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside810.7% Upside$12.75 Price TargetShort InterestHealthy4.88% of Shares Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$27,433 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.88) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.13 out of 5 starsMedical Sector150th out of 910 stocksPharmaceutical Preparations Industry56th out of 426 stocks 3.2 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Marinus Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.88% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 60.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.55. Previous Next 2.8 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Marinus Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows13 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,433.00 in company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Marinus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.88) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Marinus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More MRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Stock News HeadlinesAugust 8, 2024 | insidertrades.comInsider Selling: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) CEO Sells 12,145 Shares of StockAugust 28, 2024 | americanbankingnews.comStockNews.com Lowers Marinus Pharmaceuticals (NASDAQ:MRNS) to SellSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 28, 2024 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.comAugust 27, 2024 | msn.comMarinus Pharmaceuticals Hosts Investor and Analyst DayAugust 21, 2024 | msn.comMarinus Pharmaceuticals Reports Robust Q2 2024 Financial Results and Business ProgressAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals on Strong Ztalmy Sales and Promising Pipeline DevelopmentsAugust 16, 2024 | finance.yahoo.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 15, 2024 | money.usnews.comMarinus Pharmaceuticals IncAugust 15, 2024 | markets.businessinsider.comMaintaining Hold on Marinus Pharmaceuticals Amid Financial Uncertainty and Pipeline PotentialAugust 15, 2024 | msn.comLadenburg Thalmann Downgrades Marinus Pharmaceuticals (MRNS)August 14, 2024 | markets.businessinsider.comMarinus Pharmaceuticals earnings preview: what Wall Street is expectingAugust 14, 2024 | finance.yahoo.comMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals on Strong ZTALMY Performance and Promising Pipeline OutlookAugust 13, 2024 | businesswire.comPacific Defense Announces US Army CMFF Program TeamAugust 7, 2024 | stockhouse.comInvestors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law FirmAugust 6, 2024 | msn.comMarinus Pharmaceuticals to Announce Q2 Financial ResultsSee More Headlines Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$12.75 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+810.7%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-493.14% Pretax Margin-493.14% Return on Equity-7,831.35% Return on Assets-98.83% Debt Debt-to-Equity Ratio5.68 Current Ratio2.28 Quick Ratio2.15 Sales & Book Value Annual Sales$30.26 million Price / Sales2.54 Cash FlowN/A Price / Cash FlowN/A Book Value($0.86) per share Price / Book-1.63Miscellaneous Outstanding Shares54,934,000Free Float51,935,000Market Cap$76.91 million OptionableOptionable Beta1.13 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Scott N. Braunstein M.D. (Age 61)CEO, President & Chairman Comp: $1.01MDr. Alex Aimetti Ph.D.Chief Scientific OfficerMs. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate AffairsMs. Martha E. Manning Esq. (Age 69)J. D., Senior VP, General Counsel & Secretary Molly CameronDirector of Corporate Communications & Investor RelationsDr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance OfficerMr. Thomas J. LyonsChief Business OfficerMr. David CzekaiSenior Vice President of Chemistry, Manufacturing & ControlsDr. Mark Paternoster Ph.D.Senior Vice President of DevelopmentDr. Dayong Li Ph.D.Senior Vice President of BiometricsMore ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTPuma BiotechnologyNASDAQ:PBYIKamadaNASDAQ:KMDAZevra TherapeuticsNASDAQ:ZVRABlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsPoint72 Asia Singapore Pte. Ltd.Bought 54,878 shares on 8/15/2024Ownership: 0.100%AQR Capital Management LLCBought 12,934 shares on 8/15/2024Ownership: 0.057%Squarepoint Ops LLCBought 175,735 shares on 8/14/2024Ownership: 0.320%Point72 DIFC LtdBought 23,698 shares on 8/14/2024Ownership: 0.043%Torno Capital LLCSold 200 shares on 8/14/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MRNS Stock Analysis - Frequently Asked Questions How have MRNS shares performed this year? Marinus Pharmaceuticals' stock was trading at $10.87 at the beginning of 2024. Since then, MRNS shares have decreased by 87.1% and is now trading at $1.40. View the best growth stocks for 2024 here. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.01. The biopharmaceutical company earned $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative trailing twelve-month return on equity of 7,831.35%. When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals shares reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Marinus Pharmaceuticals' major shareholders? Top institutional investors of Marinus Pharmaceuticals include Acadian Asset Management LLC (1.27%), Renaissance Technologies LLC (1.13%), Assenagon Asset Management S.A. (0.47%) and XTX Topco Ltd (0.36%). Insiders that own company stock include Scott Braunstein, Steven Pfanstiel, Christina Shafer and Martha E Manning. View institutional ownership trends. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN) and Realty Income (O). This page (NASDAQ:MRNS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.